Previous 10 | Next 10 |
Agenus's balstilimab and zalifrelimab nears FDA submission for cervical cancer. Seattle Genetics presented tisotumab vedotin cervical cancer data at ESMO. They may compete in the marketplace despite differing mechanisms of action. For further details see: Agenus Vs. Seat...
MK-4830 Phase 1 early results are positive. Value, if commercialized, could be on par with CTLA-4 inhibitors. This is another proof of the value of the Agenus clinical and preclinical pipeline. For further details see: Agenus First Data From MK-4830: Another Reason To Bu...
Agenus (NASDAQ: AGEN ) announced the initiation of the rolling submission of its Biologics License Application to the U.S. FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer. More news on: Agenus Inc., Healthcare stocks news, Read more ...
LEXINGTON, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the initiation of ...
Cassava Sciences (NASDAQ: SAVA ) +27% on insider buying. More news on: Cassava Sciences, Inc., Immutep Limited, ClearOne, Inc., , Stocks on the move, Read more ...
Agenus (NASDAQ: AGEN ) presents preliminary results from two large clinical trials of more than 150 patients in patients with recurrent/metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Population data cut-off: July 31, 2020 More news...
160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients 155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 positive pati...
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jen...
LEXINGTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Dav...
Are These WeBull & Robinhood Penny Stocks On Your List This Week? Whether you’re looking for penny stocks to buy on Robinhood, WeBull, or other brokers, it’s good to have a strategy in place, first. One of the quickest ways to cut through the noise is to find companies with...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...